X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 (-) 2014 2013 2012 2011 2010 2009 Reset 2014 December 10, 2014 arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire December 7, 2014 arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model November 13, 2014 arGEN-X – Third Quarter Business Update November 10, 2014 arGEN-X Initiates Clinical Efficacy Evaluation of ARGX-110 in Patients with Relapsed/Refractory CD70-Positive T-Cell Lymphomas November 2, 2014 arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia October 14, 2014 arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110 September 17, 2014 arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-positive Solid Tumors into its Phase 1b Expansion Trial with ARGX-110 September 16, 2014 arGEN-X’ Core Patents Protecting Lead Clinical Candidates ARGX-110 and ARGX-111 Receive Accelerated Grant in the United States September 14, 2014 arGEN-X Appoints Petercam NV as Liquidity Provider to Facilitate Trading on Euronext Brussels August 26, 2014 arGEN-X – Business Update and First Half 2014 Results August 18, 2014 arGEN-X Announces Positive Preclinical Results for ARGX-113 August 10, 2014 arGEN-X Raises Additional €1.8 million via Exercise of Over-allotment Option and Announces the End of the Stabilization Period Pagination Current page 1 Page 2 Next page Next › Last page Last »